Blog
Oral Contraceptive Use and Female Hair Loss

A recent groundbreaking study funded by the British Skin Foundation and published in the JAMA Dermatology journal has shed light on the potential link between oral contraceptive use and the development of frontal fibrosing alopecia (FFA), a condition leading to irreversible hair loss primarily in women. This research could pave the way for new preventive and therapeutic strategies for this distressing condition.
Understanding Frontal Fibrosing Alopecia (FFA)
Frontal fibrosing alopecia (FFA) is a skin disorder characterized by inflammation, scarring, and hair loss, often resulting in a receding hairline. Since its first medical description in 1994, the number of FFA cases has been on the rise. The condition’s exact mechanism remains unclear, but it is believed to result from a combination of genetic and environmental factors.
The Genetic Connection
The study, led by Dr. Christos Tziotzios from St. John’s Institute of Dermatology at King’s College London, alongside Prof. Michael Simpson, Prof. John McGrath, and Dr. Tuntas Rayinda, focused on the role of the CYP1B1 gene. This gene encodes an enzyme crucial in the metabolism of exogenous hormones, including those found in oral contraceptives.
Women possessing a specific version of the CYP1B1 gene who used oral contraceptives were found to have a higher likelihood of developing FFA. This discovery underscores the hypothesis that FFA arises from a combination of genetic susceptibility and environmental influences, such as hormone metabolism impacted by oral contraceptives.
Gene-Environment Interaction
This study represents the first gene-environment interaction study into FFA. The researchers previously established a causal link between the CYP1B1 gene and FFA. The current research extends this knowledge by examining whether oral contraceptive use could trigger FFA development in genetically predisposed women.
Data was collected between July 2015 and September 2017 from women with FFA across the UK and compared against women without FFA from the UK Biobank. The findings support the model that FFA results from a combination of genetic predisposition and environmental triggers, as highlighted by the British Skin Foundation.
Implications and Future Directions
Dr. Tziotzios emphasized the importance of this research, stating, “We have now demonstrated the contribution of oral contraceptives to disease manifestation via gene-environment interaction. We are very grateful to all our referring clinicians in the UK, all clinical and research staff, our patients, and the British Skin Foundation for financially supporting our work.”
The researchers aim to develop genetic tests to identify individuals at risk for FFA, potentially minimizing the condition’s impact. These tests are currently being refined for broader availability.